Purpose: To report a case of bullous central serous chorioretinopathy (CSCR) after starting a Janus kinase (JAK) inhibitor and describe the results of focal laser treatment. Methods: A single case was evaluated. Results: A 54-year-old man with rheumatoid arthritis presented with a 2-week history of left superior field loss. His medications included prednisone 10 mg and upadacitinib, which was added to his regimen 3 weeks previously. His visual acuity (VA) was 20/25 OD and 20/30 OS. An ophthalmic examination of the left eye found an ill-defined white lesion of 2 × 3 disc diameters at the macula with an inferior retinal detachment (RD). Optical coherence tomography showed subretinal fibrin with subretinal fluid (SRF) and a pigment epithelial detachment. After a diagnosis of bullous CSCR was made, focal laser application was performed. One year later, the patient’s VA recovered to 20/20 with resolved SRF. Conclusions: Bullous CSCR with a serous RD is an uncommon subtype of pachychoroid disease. Upadacitinib may be associated with its occurrence through disequilibrium of the coagulation cascade. Focal laser treatment offers a favorable outcome for this disease.
BalaratnasingamCFreundKBTanAM, et al. Bullous variant of central serous chorioretinopathy: expansion of phenotypic features using multimethod imaging. Ophthalmology. 2016;123(7):1541-1552. doi:10.1016/j.ophtha.2016.03.017
3.
GassJD.Bullous retinal detachment. An unusual manifestation of idiopathic central serous choroidopathy. Am J Ophthalmol. 1973;75(5):810-821. doi:10.1016/0002-9394(73)90887-8
4.
KangHGWooSJLeeJY, et al. Pathogenic risk factors and associated outcomes in the bullous variant of central serous chorioretinopathy. Ophthalmol Retina. 2022;6(10):939-948. doi:10.1016/j.oret.2022.04.015
5.
CebeciZOrayMBayraktarŞTuğal-TutkunİKırN.Atypical central serous chorioretinopathy. Turk J Ophthalmol. 2017;47(4):238-242. doi:10.4274/tjo.38039
6.
SahuDKNamperumalsamyPHiltonGFde SousaNF.Bullous variant of idiopathic central serous chorioretinopathy. Br J Ophthalmol. 2000;84(5):485-492. doi:10.1136/bjo.84.5.485
7.
MoriSOgataFTsunodaR.Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol. 2021;40(11):4457-4471. doi:10.1007/s10067-021-05911-4
8.
KotylaPJEngelmannMGiemza-StokłosaJWnukBIslamMA.Thromboembolic adverse drug reactions in Janus kinase (JAK) inhibitors: does the inhibitor specificity play a role?Int J Mol Sci. 2021;22(5):2449. doi:10.3390/ijms22052449
9.
Guttman-YasskyEThyssenJPSilverbergJI, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol. 2023;151(1):172-181. doi:10.1016/j.jaci.2022.09.023
10.
AndersonWJSmithBT.Bilateral bullous central serous chorioretinopathy treated with PDT and eplerenone. Am J Ophthalmol Case Rep. 2022;28:101739. doi:10.1016/j.ajoc.2022.101739
